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CONSUMER
NEWS
Pharmaceutical Industry Faces
Prescription for Change as High
Drug Prices Call Consumers
to Action
Kathyrn Smetana

I. Introduction
The rising costs of prescription drugs are attributable to any number of factors depending upon which
side of the prescription you are on. Consumers and
health care providers see major pharmaceutical companies engaging in rampant profiteering, while drug manufacturers claim high research and development costs as
justification for high purchase prices. On the attack,
pharmacies, generic drug manufacturers, and health care
providers have engaged anti-trust laws as a means to
promote less expensive alternatives for consumers. The
drug companies view changes to the system as leading to
dwindling care and stagnating research. While legislators
seek a meaningful compromise, consumers are looking
over the border and online for lower prices.
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II. Do We Get What We Pay For?
Americans spend more on prescription drugs per
person than any other nation in the world.' It is estimated
that in 2001, total spending on prescription drugs will be
$165 billion, or $575 for the average American.2 Drug
spending doubles every five years and rises three times
faster than overall health care spending. However, this
increase in spending does not correspond to a proportional increase in better health for patients.4
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The prices for these countries were extrapolated from figures given in "Prescription Drug Pricing... An
International Price Comparison" prepared for the U.S. House of Representatives on August 27, 1999. They
are not exact, but should be considered close approximations of actual costs.
The savings found in on-line pharmacies are listed drug by drug. In total, they represent a saving of more
than 19%. Even greater savings could be realized through the prudent use of generics and dosage melding
(purchasing double-strength dosages and splitting the pills.., with your doctor's approval.)

III. Why Do We Pay More?
According to a recent BlueCross BlueShield white
paper, unreasonable drug costs are the result of unconscionable industry profits.STo illustrate, pharmaceutical
industry profit margins range between 19-24%, while
other large industries have profit margins of only 3-5%.6

Pharmaceutical Research and Manufacturers of
America (PhRMA), a brand drug industry trade association, defends the profitability of the drug industry.7

PhRMA produces a brochure for consumers supporting
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the high prescription drug prices.8 They claim that the
high costs to consumers are necessary to generate enough
revenue to fund research and development costs. 9
PhRMA also admonishes consumers against purchasing
cheaper alternatives in other countries and of supporting
potential government instituted price controls. 10
PhRMA explains that high drug prices are the
inevitable result of necessary, though high priced, research and development." They state that bringing one
new medicine to the market costs $500 million, and takes
12-15 years of testing. 12 Additionally, only 3 out of 10
drugs available to Americans generate enough revenue to
13
meet or exceed research and development costs.
PhRMA stands by its estimated cost of $500 million for
each new drug brought to market, to the point of fighting
a nine year court battle that brought it to the United
States Supreme Court just to keep the General Accounting Office from seeing its Research and Development
financial records. 4
PhRMA also argues that instituting price controls
is not viable because "price controls have been tried
numerous times over the past 4,000 years but have never
worked." 15 PhRMA cites the potential for investors to
take their money elsewhere, and even resorts to scare
tactics to ward off price controls. 6 Alan Holmer, President of PhRMA, stated, "if we impose price controls...
it's going to harm my kids and it's going to harm those
millions of Americans who have life-threatening conditions." 7 According to PhRMA, keeping the strong free
market in pharmaceutical drugs is necessary for innovation and better health, while challenging the system will
naturally result in halting health care progress. 8
However, the prescription drug industry fails to
mention that it spends more on direct consumer advertising and promotion for new drugs than it spends funding
research and development of the drugs. 19 The result is
that new drugs with heavy advertising can cost significantly more than their comparable predecessors.2 °
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In some instances, these new drugs are actually less
effective than their older counterparts. 21 At the same time,
PhRMA admits that pharmaceutical companies put only
one out of every five dollars of revenue into research and
development."'
Furthermore, PhRMA fails to mention that over
75% of the drugs brought to market are not innovative,
nor do they provide important therapeutic gains, rather
these drugs, often called "me-too" drugs, provide no
benefit over already existing products, and generally
have research and development costs significantly lower
than actual innovative drugs.23 Conspicuously absent
from PhRMA's statements is any evidence of realizable
consumer value, or any effort to compromise for those
consumers unable to bear the cost of their innovative,
thoroughly researched prescription medication.

IV. Reactions to High Prices
The increase in prices of commonly prescribed
medications has affected such a wide population that
response is inevitable. Various groups, from drug manufacturers to medical professionals to congressmen and
consumers have challenged high priced medications in
ways unique to the resources available to each.
A. Court Cases - Anti-Trust Violations
On June 6, 2000, the United States District Court
for the Eastern District of Michigan, Southern Division, in
In re Cardizem CD Antitrust Litigation, entered partial
summary judgment in favor of plaintiffs alleging violations of anti-trust laws against defendant pharmaceutical
companies HMRI and Andrx for entering into an agreement that restrained generic competition in the market
for Cardizem CD, a widely prescribed heart
medication.24 The court found that HMRI and Andrx
agreed to restrain Andrx from marketing a generic verLoyola Consumer Law Review
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sion of Cardizem CD, which inhibited generic competition throughout the life of the agreement, effectively
allowing HMRI to fix the price of the drug at non-competitive levels.25 To keep Andrx from marketing a generic
Cardizem CD, HMRI agreed to pay Andrx $10 million
per quarter.26 The court stated that this agreement was "a
straight forward horizontal market allocation agreement
[that] fits within the category of business practices which
have long been held illegal per se under section 1 of the
27
Sherman Act.
Similarly, in December 2000, the United States
District Court for the Southern District of Florida, Southern Division, in In re Terazosin Hydrochloride Antitrust
Litigation granted summary judgment to plaintiffs against
defendant drug manufacturers for engaging in an
agreement to fix the price of a drug used to treat hypertension and enlarged prostates.28 In this instance, Abbott
Laboratories contracted with Zenith and Geneva Pharmaceuticals such that Zenith agreed to accept $6 million
per quarter, and Geneva $4.5 million per month, to refrain from marketing generic equivalents of Terazosin
Hydrochloride. 29 These agreements were found to be
"classic examples" of per se violations of anti-trust laws.30
Most recently, in August 2001, the New York City
Patrolmen's Benevolent Association ("PBA") President,
Patrick J. Lynch, filed four federal class-action suits in
four states charging nine pharmaceutical companies with
violations of anti-trust laws by entering into agreements
to keep cheaper generic drugs off the market, alleging
costs to consumers in the multi-million dollar range.3
Alleging that the anti-trust violations primarily affect the
elderly, breast cancer victims, and those suffering from
hypertension, angina and anxiety, Lynch commented that
the agreements made between drug companies force
consumers "to pay artificially high prices for very important, common medications." 32 Of the suits filed, one in
West Virginia alleges that Pfizer entered into an agreement with Mylan Labs to extend Pfizer's monopoly in
Volume 14, Number 1 2001
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the market for Procardia XL 30, a drug prescribed for
hypertension and angina, while staving off entry in the
market of generic alternatives. 33 As a result of this agreement, the complaint alleges that there was no true generic alternative available until at least February 6, 2001,
which meant there was no choice but to pay inflated
prices until that time.34 Suits filed in the Eastern District
of New York and in Newark allege manufacturers of the
most widely prescribed breast cancer drug, and of the
fourth most prescribed drug for the elderly, respectively,
cooperated to hold prices at an artificially high level,
while blocking a cheaper generic alternative from entering the market.3 5 Finally, a suit filed in the District of
Columbia alleges that Bristol-Myers Squibb extended its
monopoly on a common anti-anxiety drug by falsifying
patent information.36
B. Medical Professionals Offer Suggestions
Medical professionals have provided congressional testimony to support alternatives to the high costs
associated with prescription medication.37 To balance the
competing interests of the pharmaceutical companies and
consumers, federal subsidies appear a viable option that
would not only lower direct cost to consumers, but also
ensure profits to the drug industry.38 Additional suggestions include cutting the growing marketing budgets of
the large brand name companies, providing cost to efficacy estimates for medications to physicians and patients
to determine what medications are worth the cost, and to
establish reasonable ceilings on profits.39
C. Congressmen Propose Legislation
Members of Congress have endeavored against
high drug prices by introducing legislation calling for
change as a means to garner some relief to constituents'
pocketbooks. Among others, Vermont Congressman,
Loyola Consumer Law Review
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Bernie Sanders, introduced an amendment to the House
calling for an end to the "outrageously" high cost of
prescription medications, stating that Americans are
"being ripped off."' The amendment would require drug
companies
to market prescription drugs at "reasonable"
prices.441
D. Consumers Take Action
While Congress considers new legislation, and
courts settle legal disputes, consumers aren't waiting
around, instead they are getting their medications at the
lowest price they are able to find them. In a recent survey,
over 60% of Americans said they would drive to Canada
to get their prescriptions at a lower price if they lived
closer.4 2 The average price of brand name drugs in
Canada run 62.5% of the price in the United States.43 It is
estimated that thousands of Americans near the Canadian border currently drive across to fill their prescriptions to take advantage of the lower prices. 44 Stories of
busloads of seniors making regular treks across the
border for prescription savings have become lore. If
Americans had the ability to pay average Canadian
prices for brand name drugs this year, the savings would
total an estimated $38.4 billion.45
Consumers without the ability to travel over the
border to get prescription medications at a lower cost
have found the Internet an invaluable source of both
information and medications. One consumer, 65 years
old and uninsured, faced a $6,000 annual prescription bill
in America until he discovered the discounted prices in
Canada.' He went on to found Medicine Express, a club
connecting seniors with a doctor and pharmacy in
Niagara Falls, Canada.4 7 Another went as far as Sri Lanka
for medication to treat his thyroid condition after he
found himself uninsured and unable to pay American
prices." This same consumer has published an informational book detailing the process of purchasing medicaVolume 14, Number 1 2001
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tion abroad via email, which has sold nearly 3,000 copies
to date.49
A new online pharmacy slated to launch in January 2002, LePharmacy.com, out of Montreal, boasts the
ability to offer American consumers prescription drugs at
a savings of 40 - 70%.50 Several Canadian based websites
sell prescription medications at a cheaper price to Americans, and over the counter Canadian medications that
require prescriptions to procure in America.5' Visiting
websites is much lauded method of bypassing high
prices in the States while also finding competitive pricing
for necessary medications as well as lifestyle drugs like
Viagra.

V. Conclusion
It is unclear what rules of conduct will be carved
out for the drug industry by litigation and legislation, but
major pharmaceutical companies standing to lose enormous profits solidly oppose changing the trend toward
rising prices. PhRMA's senior director of policy, Tracy
Baroni, dramatically predicts that if the government
acted to lower prescription drug prices, "'[the lights go
out in the labs, and there is no R&D."' 52
Rallying against artificially high prescription
prices, seemingly diverse groups ranging from medical
professionals, to Congress, as well as competing drug
manufacturers have challenged the dominating pharmaceutical companies, with mixed result. The drug industry, reaping profits other industries can only hope to
achieve, is not surprisingly, a stalwart foe. However,
with skyrocketing prescription drug prices, consumers
whose incomes cannot abide such increases will continue
to seek the lowest prices outside the U.S. Some caution
against purchasing medication from countries without
the safety checks and standards of the FDA; that without
FDA approval, consumers run the risk of not knowing
what they're getting. 3 However, the consumer voice
Loyola Consumer Law Review
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overwhelms this concern - the savings are far more
meaningful than the strictures of FDA process.
PhRMA insists on maintaining the free market
system as a means to achieve innovation in health care
for the future, but what the major pharmaceutical companies may not be willing to accept is that the free market
system is a double-edged sword, for consumers will only
pay so much for so long before cheaper options in other
markets become the only answer to health care in the
future.
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